0216/26SCR018-12/R4RGB
Media Highlights
From the 2025 ASH Annual Meeting
3
Media Outlet Article / Coverage
Cancer Nursing Today Investigating Safety and Feasibility of Axatilimab Dosing
Regimens in Patients with GVHD: Dr. Farhadfar Shares
Research Insights
Cure Higher Niktimvo Dosing Feasible in Chronic Graft-Versus-
Host Disease
Gene Online Senti Bio Wins FDA RMAT Designation for SENTI-202 on
50% Response Rate in Leukemia Trial
OncLive Axatilimab Dosing Shift Shows Feasibility in cGVHD
Oncology Nursing News Axalitimab Dose Transition Appears Feasible, Tolerable in
cGVHD
Targeted Oncology Higher, Monthly Dosing of Axatilimab Feasible, Tolerable in
cGVHD
VuMedi ASH 2025 Insights: Promising Results From an Ongoing
Phase I Multicenter Study of SENTI-202, a First-in-Class,
CD33 and/or FLT3 NOT Endomucin, Selective Off-The-Shelf
Logic Gated CAR NK Cell Therapy in Adults With R/R AML
VuMedi ASH 2025 Insights: Safety and Feasibility of 0.6 mg/
kg Every 4 Weeks Dosing of Axatilimab in Patients With
cGVHD Treated in the AGAVE-201 Study
Nosha Farhadfar, MD
SCRI at Methodist Healthcare
